ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

KRAS G12D Inhibitor VS-7375

Also written as “GFH375”, “VS-7375” and “GFH375 + Cetuximab”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Pancreatic Neoplasms · Colorectal Neoplasms, led by 2 companies.

Drug pageKRAS G12D Inhibitor VS-7375: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 20, 202512 company-led studies, 11 open or runningNext primary completion: Apr 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Genfleet Therapeutics (Shanghai)its history only87 open or runningphase 3since Nov 20, 2025Jul 8, 2024Apr 30, 2027phase 2 · NCT07554859
Verastem44 open or runningphase 2since May 26, 2025May 26, 2025Jun 2027phase 2 · NCT07659795

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Verastem only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 26, 2025First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT07020221 · 616 planned · United States, Australia, France and more
  2. May 26, 2026Phase 2 study in Pancreatic NeoplasmsNCT07644559 · 185 planned · United States, Australia, Canada and more
  3. Jun 15, 20262 phase 2 studiesNCT07659795, NCT07659782

Ahead

  1. Jun 2027Primary completion: phase 2 study in Colorectal NeoplasmsNCT07659795
  2. Jun 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07659782
  3. Jun 2027Primary completion: phase 2 study in Pancreatic NeoplasmsNCT07644559
  4. Dec 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07020221

TargetBeta

KRAS →read by rule
“An orally bioavailable non-covalent small molecule inhibitor of both the active, guanosine triphosphate (GTP)-bound form and the inactive, guanosine diphosphate (GDP)-bound form of the oncogenic KRAS substitution mutation G12D, ”NCIt, by rule

Other programs on KRAS

ProgramCompanyFurthest phaseStudies
sotorasibruleAmgenphase 328
adagrasibruleBristol-Myers Squibbphase 316
olomorasibEli Lillyphase 316
divarasibHoffmann-La Rochephase 313
glecirasibruleAllist Pharmaceuticalsphase 312
calderasibMerckphase 312
daraxonrasibruleRevolution Medicinesphase 310
garsorasibruleInventisBiophase 38
KRAS G12D Inhibitor HRS-4642Jiangsu HengRui Medicinephase 37
zoldonrasibruleRevolution Medicinesphase 36
HRS-7058Jiangsu HengRui Medicinephase 36
opnurasibruleNovartisphase 35

Studies

All 4 Verastem leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07659795Colorectal Neoplasms · United States, Australia, Belgium and more2RecruitingJun 2027150
NCT07659782Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more2RecruitingJun 2027105
NCT07644559Pancreatic Neoplasms · United States, Australia, Canada and more2RecruitingJun 2027185
NCT07020221Carcinoma, Non-Small-Cell Lung · United States, Australia, France and more2RecruitingDec 2028616

How it is read

Names in the registry

  • “GFH375”, 7 entries
  • “VS-7375”, 4 entries
  • “GFH375 + Cetuximab”, 1 entry
  • “ArmA:GFH375”, 1 entry
  • “Arm B:GFH375”, 1 entry

Codes read as this program: GFH375.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.